Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on PYX-201 program December 26, 2024
DSMB recommends continuation of Ph 3 study of Bria-IMT™ + an immune checkpoint inhibitor in metastatic breast cancer patients December 10, 2024
Datopotamab Deruxtecan and Datopotamab Deruxtecan + Durvalumab Arms completed in the I-SPY2 Trial for Stage 2/3 Neoadjuvant Breast Cancer December 10, 2024
FDA Orphan Drug Designation for Azeliragon for the Treatment of Brain Metastasis From Breast Cancer December 10, 2024
Olema Oncology Announces New CTA and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement December 4, 2024
Kisqali receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence December 4, 2024
Incyclix Bio and Lilly to test INX-315 + Verzenio and Fulvestrant in HR+/HER2- Breast Cancer November 26, 2024
ALISCA-Breast1 Ph 2 Trial of Alisertib initiated in HR+ve, HER2-Negative Metastatic Breast Cancer November 26, 2024
Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer Released November 5, 2024
FDA Clears IND Application for ATX-559 Ph 1 study in solid tumor patients with a focus on BRCA1/2-deficient breast cancer and MSI-H and dMMR solid tumors October 29, 2024
Additional data from Ph 1 open-label, dose-escalation trial of PRT3789 in breast cancer patients with a SMARCA4 mutation announced October 29, 2024
Positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer October 22, 2024
35 sites active and enrolling in pivotal Ph 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC) October 22, 2024
IND Application for Ph 3 Study of Neoadjuvant KN026 +Albumin-bound Docetaxel in Breast Cancer Approved October 22, 2024
FDA approves Itovebi for advanced HR+ve, HER2-neg breast cancer with a PIK3CA mutation October 15, 2024
Enhertu granted Priority Review in the US for patients with HER2-low/ultralow metastatic breast cancer who received at least one line of endocrine therapy October 8, 2024
Key Progress and Upcoming Studies for Pelareorep Breast and Pancreatic Cancer Treatments Announced in Preparation for FDA Accelerated Approval Path October 8, 2024
ENHERTU® Supplemental NDA Submitted in Japan for Patients with HER2 Low/ultralow Metastatic Breast Cancer October 8, 2024
Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor’s Portfolio of next-gen CDK inhibitors for Treating Breast Cancer October 2, 2024
FAILED TRIAL: Datopotamab deruxtecan did not achieve statistical significance for OS vs chemo in patients with metastatic HR+, HER2-low or neg breast cancer in TROPION-Breast01 Ph 3 trial September 24, 2024
